WDWilfred F. A. Den Dunnen

Wilfred F. A. Den Dunnen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wilfred F. A. Den Dunnen has a total of 357 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A clinicopathological prediction model for remission after transsphenoidal surgery for acromegaly: A retrospective single-center cohort study

    by Rob A. Vergeer, Henriette E. Westerlaan, Annet Willems, Anke D. van Den Beukel, Friederike E. Roelandt-Schumann, Henk J. Buikema, Jos M.A. Kuijlen, J. Marc C. van Dijk, Melanie M. van der Klauw, Anneke C. Muller-Kobold, et al.

    Transsphenoidal surgery (TSS) is the primary treatment of choice in acromegaly. Previous research on predicting remission after TSS was mainly based on clinical and radiological data, lacking histopathological evaluation. Our aim is to produce a clinicopathological prediction model for remission after TSS in acromegaly, enabling clinicians to better inform patients on expected treatment outcomes. This single-center study involved retrospective data collection in a large tertiary referral center in The Netherlands. One hundred patients in whom TSS was performed as primary therapy between January 2000 and July 2019 were included. Uni- and multivariate regression models were used to identify predictors of early biochemical remission according to the consensus criteria, long-term remission (defined as an age- and sex-normalized Insuline growth like factor 1and the absence of postoperative treatment (radiation therapy, repeat surgery, or medical therapy) at last follow-up, irrespective of residual tumor on postoperative magnetic resonance imaging ), and long-term remission without residual tumor (defined by the same biochemical and treatment criteria with the additional absence of residual tumor on postoperative magnetic resonance imaging ). In univariate logistic regression, a larger tumor volume, a larger maximum tumor diameter, a higher modified Knosp classification grade, the presence of cavernous sinus invasion, and a higher random growth hormone at diagnosis were significantly associated with lower remission rates. Tumor subtype and proliferation markers were not. In multivariate logistic regression, a simple model with only maximum tumor diameter as an independent variable predicted best for early biochemical remission (OR 0.85, 95% CI 0.78–0.93, P < .001, sensitivity 78.9%, specificity 71.8%), long-term remission (OR 0.79, 95% CI 0.70–0.88, P < .001, sensitivity 79.5%, specificity 73.7%), and long-term remission without residual tumor (OR 0.75, 95% CI 0.66–0.86, P < .001, sensitivity 79.4%, specificity 78.0%). Maximum tumor diameter was the best predictor, while histopathological characteristics were not predictive for remission after TSS in acromegaly in this cohort.

  • Open Access

    Microfluidic compartmentalization reveals that ferrostatin-1 restores directional mitochondrial transport in Aβ-challenged neurons

    by Nad'A Majerníková, Beatrice Corci, Yuequ Zhang, Tingting Chen, Maaike van Koeveringe, Denice Mensinga, Patty P. M. F. A. Mulder, Elisabeth Verpoorte, Andrea Mattarei, Diana Pendin, et al.

    Aβ 1–42 induces increased retrograde transport of axonal mitochondria and deregulation of mitochondrial calcium, which can be prevented by Fer-1.

  • Open Access

    Selective resection of the medial wall of the cavernous sinus in acromegaly: patient series

    by Rob A. Vergeer, Mark R. Postma, Melanie M. van der Klauw, Astrid G. W. Korsten-Meijer, Robert A. Feijen, Wilfred F. A. Den Dunnen, J. Marc C. van Dijk, Jos M. A. Kuijlen

    BACKGROUND: Transsphenoidal surgery (TSS) is the primary treatment of choice in acromegaly. Tumor invasion into the medial wall of the cavernous sinus (MWCS) has been observed, even in Knosp grades 0–2, and may lead to suboptimal surgical results if not additionally resected. Removal of the MWCS may enhance the surgical outcome and result in improved endocrine remission rates. The aim of this study was to evaluate the impact of additional MWCS resection during TSS for acromegaly on endocrine remission and complication rates. The authors prospectively collected the data of acromegaly patients at a large tertiary pituitary referral center. Between January 2023 and January 2025, patients treated with TSS and additional selective resection of the MWCS were included. Patient demographics, tumor characteristics, surgical outcome, and postoperative complications were reviewed. OBSERVATIONS: Twelve patients were included (9 primary TSS, 3 re-TSS). Tumor invasion of the MWCS was confirmed in 91.7%. The median follow-up was 19 months (range 3–27 months). After primary TSS, 8 of 9 patients (88.9%) were in endocrine remission. Following re-TSS, remission was observed in 33.3%. Ultimately, disease control was achieved in 11 of 12 patients (91.7%). No carotid injuries or permanent neurological deficits were observed. LESSONS: Additional selective resection of the MWCS during TSS in acromegaly is a technique that can be safely executed, and it seems to enhance endocrine remission rates especially in primary TSS. https://thejns.org/doi/10.3171/CASE2665

  • Open Access

    Ferroptosis inhibition protects against α-synuclein-related neuronal cell death

    by Naďa Majerníková, Maria J. Caiado, Renée I. Seinstra, Suzanne Couzijn, María E. Goya, Casandra Salinas Salinas, Hannah Truong, Tineke van der Sluis, Anneke Miedema, Leon C. L. T. van Kempen, et al.

    Parkinson’s disease (PD), characterized by α-synuclein (α-syn) pathology, affects millions of people worldwide. While current treatments mainly symptomatically address the motor aspects of PD, they lack efficacy in delaying or halting the degenerative process. Ferroptosis, a type of programmed cell death characterized by iron-dependent lipid peroxidation, has been previously linked to PD. Advancing the development of neuroprotective treatments hinges on comprehending the interplay between PD’s pathological hallmarks and cell death. We examined six ferroptosis-related markers (ferroportin, ferritin, NCOA4, cytochrome c, GPX4, and 4HNE) in mesencephalic tissues from 10 PD patients and 11 age-matched controls. In post-mortem brains of controls, several ferroptosis-related markers were differentially expressed in functional subregions of the substantia nigra (SN), suggesting differential ferroptosis vulnerability. Moreover, ferritin and ferroportin levels were reduced in relation to α-synuclein pathology, indicating impaired iron storage and export, and suggesting increased vulnerability to ferroptosis in Parkinson’s disease. Additionally, using digital spatial transcriptomics, we revealed ferroptosis-related differentially expressed genes (DEGs) in PD, which altogether pointed towards higher ferroptosis vulnerability in PD compared to control brains. To support our post-mortem findings, we used in vitro models (LUHMES neurons and mouse cortical neurons (PCNs)) and an α-syn overexpression C. elegans model. Co-treatment with low concentrations of α-syn and RSL3, which alone did not cause cell death, increased neuronal vulnerability to cell death, which was mitigated by ferrostatin-1 (Fer-1) but not deferoxamine (DFO) in cortical and dopaminergic neurons. Finally, α-syn expression in C. elegans increased iron levels, exacerbated by ferritin knockdown and reduced by DFO, which decreased α-syn inclusions. These results indicate that α-syn-related cell death can be altered by ferroptosis inhibition, and targeting the ferroptosis pathway could reduce or slow cell death associated with PD pathology. However, ferroptosis vulnerability appears cell- and model-dependent, suggesting effective therapeutic strategies may require a more comprehensive approach, targeting multiple aspects of the pathway while considering timing to achieve optimal outcomes.


  • Open Access

    Post‐COVID‐19 condition: clinical phenotypes, pathophysiological mechanisms, pathology, and management strategies

    by Larissa E Vlaming‐Van Eijk, Guolu Tang, Arno R Bourgonje, Wilfred F A Den Dunnen, Jan‐Luuk Hillebrands, Harry van Goor

    Post‐COVID‐19 condition (PCC), also known as long COVID, is a complex multiple organ system condition that can develop and persist for months after acute COVID‐19. PCC encompasses a wide range of symptoms, resulting in heterogeneous clinical manifestations. These manifestations likely arise from diverse underlying pathophysiological mechanisms, which, in turn, are influenced by risk factors such as age, sex, and comorbidities. To this end, characterising clinical phenotypes of PCC is essential for deepening our understanding of its (potentially) distinct pathophysiological mechanisms and for advancing diagnostic and patient‐tailored management strategies. PCC is thought to result from a complex interaction of various pathophysiological mechanisms, leading to functional and structural pathological alterations across multiple organ systems. Investigating these alterations is critical to improving our currently incomplete understanding of PCC's complex pathophysiology. This review provides an overview of the main clinical phenotypes of PCC, characterises these phenotypes by examining symptoms and signs, as well as the associated risk factors. The main hypothesised pathophysiological mechanisms are discussed by outlining the current knowledge on PCC pathology, focussing on the most commonly affected organ systems. Current PCC management includes supportive care such as physiotherapy and the repurposing of existing drugs primarily targeting persistence of SARS‐CoV‐2 (e.g. antivirals, monoclonal antibodies) and immune dysfunction (e.g. antiinflammatory drugs, immunomodulators). To date, prevention of SARS‐CoV‐2 infection remains critical, which can be achieved through effective public health measures and vaccination strategies. Finally, this review highlights current knowledge gaps and proposes future research directions to advance the understanding and treatment of PCC. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.


  • Xenoferroptosis, a double-hit challenge for regulated cell death

    by Teresa Mitchell-Garcia, Maria João da Costa Caiado, Qiwen Tang, Leshan Zhang, Carolina Sagarminaga Cañadas, Hong Yan, Wilfred Den Dunnen, Martina Schmidt, Amalia M. Dolga

    Ferroptosis is a regulated form of cell death driven by iron-dependent lipid peroxidation. Recent evidence indicates that ferroptosis is a critical player associated with cell death and inflammatory processes in neurodegenerative diseases, such as Alzheimer’s and Parkinson’s disease, as well as in chronic inflammation. In addition, during aging, the expression and activity of various proteins and cellular processes associated with the ferroptotic pathway, such as lipid peroxidation, have been shown to be altered. In this review, we introduce the concept of xenoferroptosis, a process in which ferroptotic signalling is amplified through the combined action of distinct challenges: one involving sub-threshold ferroptosis-related mechanisms, and another involving sub-toxic levels of exogenous or endogenous stressors. Exogenous challenges, such as air pollutants, pesticides, and micro- or nanoplastics, can disrupt redox balance through increased reactive oxygen species production, and impaired antioxidant defences. Endogenous triggers could include misfolded, aggregated proteins, such as amyloid-beta, hyperphosphorylated tau, and alpha-synuclein, which sensitize cells by promoting redox imbalance and mitochondrial dysfunction. While each individual stressor, either endogenous/exogenous or ferroptotic-associated process, may be sublethal, their convergence would initiate a synergistic cascade that accelerates cell death. We propose that xenoferroptosis represents a distinct pathogenic axis at the intersection of molecular pathology and environmental exposure, offering new perspectives for therapeutic interventions that target its dual-trigger mechanisms.

  • Open Access

    Iron(ing) out parkinsonisms: The interplay of proteinopathy and ferroptosis in Parkinson's disease and tau-related parkinsonisms

    by Maria João da Costa Caiado, Amalia M. Dolga, Wilfred F.A. Den Dunnen


  • Open Access

    The link between amyloid β and ferroptosis pathway in Alzheimer’s disease progression

    by Naďa Majerníková, Alejandro Marmolejo-Garza, Casandra Salinas Salinas, Minh D. A. Luu, Yuequ Zhang, Marina Trombetta-Lima, Tamara Tomin, Ruth Birner-Gruenberger, Šárka Lehtonen, Jari Koistinaho, et al.

    Alzheimer’s disease (AD) affects millions of people worldwide and represents the most prevalent form of dementia. Treatment strategies aiming to interfere with the formation of amyloid β (Aβ) plaques and neurofibrillary tangles (NFTs), the two major AD hallmarks, have shown modest or no effect. Recent evidence suggests that ferroptosis, a type of programmed cell death caused by iron accumulation and lipid peroxidation, contributes to AD pathogenesis. The existing link between ferroptosis and AD has been largely based on cell culture and animal studies, while evidence from human brain tissue is limited. Here we evaluate if Aβ is associated with ferroptosis pathways in post-mortem human brain tissue and whether ferroptosis inhibition could attenuate Aβ-related effects in human brain organoids. Performing positive pixel density scoring on immunohistochemically stained post-mortem Brodmann Area 17 sections revealed that the progression of AD pathology was accompanied by decreased expression of nuclear receptor co-activator 4 and glutathione peroxidase 4 in the grey matter. Differentiating between white and grey matter, allowed for a more precise understanding of the disease’s impact on different brain regions. In addition, ferroptosis inhibition prevented Aβ pathology, decreased lipid peroxidation and restored iron storage in human AD iPSCs-derived brain cortical organoids at day 50 of differentiation. Differential gene expression analysis of RNAseq of AD organoids compared to isogenic controls indicated activation of the ferroptotic pathway. This was also supported by results from untargeted proteomic analysis revealing significant changes between AD and isogenic brain organoids. Determining the causality between the development of Aβ plaques and the deregulation of molecular pathways involved in ferroptosis is crucial for developing potential therapeutic interventions.


  • Open Access

    Systemic oxidative stress may be associated with reduced IgG antibody titers against SARS-CoV-2 in vaccinated kidney transplant recipients: A post-hoc analysis of the RECOVAC-IR observational study

    by Larissa E. van Eijk, Arno R. Bourgonje, A. Lianne Messchendorp, Marian L.C. Bulthuis, Marjan Reinders-Luinge, Berber Doornbos-Van der Meer, Johanna Westra, Wilfred F.A. Den Dunnen, Jan-Luuk Hillebrands, Jan-Stephan F. Sanders, et al.


  • Open Access

    The Correlation of In Vivo MR Spectroscopy and Ex Vivo 2-Hydroxyglutarate Concentration for the Prediction of Isocitrate Dehydrogenase Mutation Status in Diffuse Glioma

    by Bart R. J. van Dijken, Hanne-Rinck Jeltema, Justyna Kłos, Peter Jan van Laar, Roelien H. Enting, Ronald G. H. J. Maatman, Klaas Bijsterveld, Wilfred F. A. Den Dunnen, Rudi A. Dierckx, Paul E. Sijens, et al.

    Isocitrate dehydrogenase (IDH) mutation status is an important biomarker in the glioma-defining subtype and corresponding prognosis. This study proposes a straightforward method for 2-hydroxyglutarate (2-HG) quantification by MR spectroscopy for IDH mutation status detection and directly compares in vivo 2-HG MR spectroscopy with ex vivo 2-HG concentration measured in resected tumor tissue. Eleven patients with suspected lower-grade glioma (ten IDH1; one IDHwt) were prospectively included. Preoperatively, 3T point-resolved spectroscopy (PRESS) was acquired; 2-HG was measured as the percentage elevation of Glx3 (the sum of 2-HG and Glx) compared to Glx4. IDH mutation status was assessed by immunochemistry or direct sequencing. The ex vivo 2-HG concentration was determined in surgically obtained tissue specimens using gas chromatography–mass spectrometry. Pearson correlation was used for assessing the correlation between in vivo MR spectroscopy and ex vivo 2-HG concentration. MR spectroscopy was positive for 2-HG in eight patients, all of whom had IDH1 tumors. A strong correlation (r = 0.80, p = 0.003) between 2-HG MR spectroscopy and the ex vivo 2-HG concentration was found. This study shows in vivo 2-HG MR spectroscopy can non-invasively determine IDH status in glioma and demonstrates a strong correlation with ex vivo 2-HG concentration in patients with lower-grade glioma.